Date: 2014-12-02
Type of information: Series B financing round
Company: Audentes Therapeutics (USA - CA)
Investors: Sofinnova Ventures (USA - CA) Venrock (USA - CA) OrbiMed (USA - NY) 5AM Ventures (USA - CA) Versant Ventures (USA - CA)
Amount: $42.5 million
Funding type: series B financing round
Planned used: Audentes Therapeutics will use this additional funding to achieve key clinical development milestones for its two lead programs for the treatment of X-Linked Myotubular Myopathy and Pompe Disease and to continue research and in-licensing efforts to become a worldwide leader in gene therapy.
Others: * On December 2, 2014, Audentes Therapeutics, a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, announced the closing of a $42.5 million Series B financing. Deerfield Management led the financing with participation from Sofinnova Ventures and Venrock. The company’s current investors, OrbiMed, 5AM Ventures, and Versant Ventures also fully participated. Jonathan Leff, a Partner on the Private Transactions team at Deerfield, will become a member of the Audentes Board of Directors as a result of the financing.
Therapeutic area: Rare diseases - Genetic diseases
